These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17205962

  • 1. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 2. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F, Sánchez de la Nieta MD, Echarri R, Anaya S, Carreño A, Vozmediano MC, Alcaide MP.
    Nefrologia; 2006 Apr; 26(3):351-7. PubMed ID: 16892824
    [Abstract] [Full Text] [Related]

  • 3. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [Abstract] [Full Text] [Related]

  • 4. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C, Multicentric group for the study of the phosphocalcic metabolism in the community of Valencia.
    J Nephrol; 2005 Jun; 18(6):739-48. PubMed ID: 16358233
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jun; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 7. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W.
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [Abstract] [Full Text] [Related]

  • 8. [Unawareness of the K/DOQI guidelines for bone and mineral metabolism in predialysis chronic kidney disease: results of the OSERCE Spanish multicenter-study survey].
    Bover J, Górriz JL, Martín de Francisco AL, Caravaca F, Barril G, Molinero LM, Grupo de Estudio OSERCE de la Sociedad Española de Nefrología.
    Nefrologia; 2008 Nov; 28(6):637-43. PubMed ID: 19016638
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM, en nombre de los investigadores del estudio OSERCE.
    Nefrologia; 2013 Jan 18; 33(1):46-60. PubMed ID: 23364626
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, Cases A.
    Nephrol Dial Transplant; 2006 Feb 18; 21(2):459-65. PubMed ID: 16263739
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
    Lee CT, Tsai YC, Ng HY, Su Y, Lee WC, Lee LC, Chiou TT, Liao SC, Hsu KT.
    J Ren Nutr; 2009 May 18; 19(3):220-7. PubMed ID: 19243976
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A.
    Iran J Kidney Dis; 2007 Jul 18; 1(1):25-8. PubMed ID: 19357440
    [Abstract] [Full Text] [Related]

  • 16. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network.
    Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC.
    Am J Kidney Dis; 2007 Feb 18; 49(2):257-66. PubMed ID: 17261428
    [Abstract] [Full Text] [Related]

  • 17. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F.
    Nephrol Dial Transplant; 2008 Jul 18; 23(7):2319-23. PubMed ID: 18281320
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S, Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2010 Aug 01; 14(4):424-31. PubMed ID: 20649764
    [Abstract] [Full Text] [Related]

  • 20. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL, Hristova M, Ho LT, Sprague SM.
    Am J Nephrol; 2007 Aug 01; 27(1):36-43. PubMed ID: 17215573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.